Adding pamidronate to standard
palliative radiotherapy may help to thwart the progression of
bone metastasis in irradiated bone and to prevent occurrences
of new bone metastases.
Turkish researchers presented their findings at the 42nd Annual
Meeting of the American Society for Therapeutic Radiology and
Oncology (ASTRO) in Boston, Massachusetts.
Melek Nur Yavuz, MD, Assistant Professor and Administrator of
the department of Radiation Oncology, Karadeniz Technical University,
Trabzon, Turkey, led the research team from that department in
undertaking this randomized trial of 50 cancer patients with
All participants were randomized equally to one of two arms. Group
1 received palliative radiation therapy plus pamidronate 90 mg,
delivered in a two-hour infusion with 0.9% sodium-chloride solution,
once every three weeks for nine months, beginning on the first
day of radiation. Group 2 received palliative radiation therapy
This study was originally undertaken to explore the possible additive
effects of pamidronate on pain palliation, quality of life, bone
mineralization, incidence of pathological fractures and new bone
metastases. Scorings were performed at baseline, week 6 and week
20 of treatment and following treatment.
No significant differences between the two groups were detected
in the changes of pain and analgesia, performance, quality of
life, serum calcium, phosphorus, alkaline phosphatases, creatinine,
transaminases, tumour markers and bone-mineral-density levels.
Thanks to Doctors' Guide for this story.
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.